Herzig Shoshana J, Rudolph James L, Haime Miguel, Ngo Long H, Marcantonio Edward R
Division of General Medicine and Primary Care, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA.
Geriatric Research Education and Clinical Center, VA Boston Healthcare System, Boston, MA ; Division of Aging, Brigham and Women's Hospital, Harvard Medical School, Boston, MA.
J Clin Trials. 2012 Jan 13;2(1):106.
Although postoperative atrial fibrillation (AF) is prevalent after cardiac surgery, the corresponding medication burden associated with this postoperative arrhythmia is unknown.
We conducted a prospective study of 204 patients aged 60 or older (median age 73) undergoing cardiac surgery at two academic medical centers. We defined "AF at discharge" as AF that developed after surgery and was present on the day of discharge. We evaluated the prevalence of anticoagulant and antiarrhythmic use at discharge, and out to 1 year post-discharge. We investigated the association between age and prescription of both classes of medications at discharge.
Ninety-one (45%) patients developed new postoperative AF, which persisted at discharge in 28 (14%) patients. Thirty-four percent of patients with postoperative AF were discharged on warfarin, 62% were discharged on antiarrhythmic medication, and 25% were discharged on both. Eighty-two percent of those discharged on both were older than 72 years of age. Patients with AF present at discharge were more likely to be discharged on anticoagulant agents than patients whose AF resolved prior to discharge (54% versus 26%, p=0.01), and more likely to be discharged on antiarrhythmic agents than patients whose AF resolved prior to discharge, though not significantly so (73% versus 57%, p=0.2). At 12 months, the proportion of patients on antiarrhythmic and anticoagulant medications had still not returned to preoperative rates.
AF persists at hospital discharge in nearly one-third of affected patients. Cardiac surgery results in the initiation of anticoagulant and antiarrhythmic medications in many older patients annually, often concurrently. Our findings underscore the need for additional studies on the natural history of this arrhythmia and clinical trials investigating different management strategies after discharge. Such research will help to inform development of guidelines addressing duration of use for these medications, to aid physicians in these complicated post-discharge management decisions.
尽管心脏手术后术后房颤(AF)很常见,但与这种术后心律失常相关的相应药物负担尚不清楚。
我们对两家学术医疗中心的204例60岁及以上(中位年龄73岁)接受心脏手术的患者进行了一项前瞻性研究。我们将“出院时房颤”定义为术后发生且出院当天仍存在的房颤。我们评估了出院时以及出院后1年内抗凝药和抗心律失常药的使用情况。我们调查了年龄与出院时这两类药物处方之间的关联。
91例(45%)患者出现了新的术后房颤,其中28例(14%)患者出院时仍持续存在。术后房颤患者中有34%出院时服用华法林,62%出院时服用抗心律失常药物,25%两者都服用。两者都服用的患者中有82%年龄超过72岁。出院时仍有房颤的患者比房颤在出院前已缓解的患者更有可能出院时服用抗凝剂(54%对26%,p = 0.01),并且比房颤在出院前已缓解的患者更有可能出院时服用抗心律失常药物,尽管差异不显著(73%对57%,p = 0.2)。在12个月时,服用抗心律失常药和抗凝药的患者比例仍未恢复到术前水平。
近三分之一的受影响患者出院时房颤仍持续存在。心脏手术导致许多老年患者每年开始使用抗凝药和抗心律失常药,且常常同时使用。我们的研究结果强调需要对这种心律失常的自然病史进行更多研究,并开展临床试验以调查出院后的不同管理策略。此类研究将有助于为制定这些药物使用时长的指南提供信息,以帮助医生做出这些复杂的出院后管理决策。